EMA Authorised: Beovu (brolucizumab) — Novartis Europharm Limited

View source ↗

Summary

The European Medicines Agency authorised Beovu (brolucizumab) by Novartis Europharm Limited for the treatment of wet age-related macular degeneration (decision …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wet Age-related Macular Degeneration

Drugs mentioned

• BEOVU (BROLUCIZUMAB)

Snippet

Status: Authorised. Therapeutic area: Wet Macular Degeneration. MAH: Novartis Europharm Limited. Decision date: 27/01/2026